John W. Marks

5 ta ish

The University of Texas MD Anderson Cancer Center

1. The rGel/BLyS Fusion Toxin Inhibits Diffuse Large B-cell Lymphoma Growth In Vitro and In Vivo

   Mi-Ae Lyu, Deepak Rai, Kwang Seok Ahn +7

   MaqolaOAOchiq kirish20102 iqtibos

   ABIABI:AkademIndex/2026.other.193212

2. The rGel/BLyS fusion toxin inhibits STAT3 signaling via down-regulation of interleukin-6 receptor in diffuse large B-cell lymphoma

   Mi-Ae Lyu, Bokyung Sung, Lawrence H. Cheung +4

   Maqola20102 iqtibos

   ABIABI:AkademIndex/2026.other.193221

3. Construction and Characterization of Novel, Recombinant Immunotoxins Targeting the <i>Her2/neu</i> Oncogene Product: <i>In vitro</i> and <i>In vivo</i> Studies

   Yu Cao, James D. Marks, John W. Marks +3

   Maqola20092 iqtibos

   ABIABI:AkademIndex/2026.other.193235

4. <i>In vitro</i> and <i>in vivo</i> studies of a VEGF ₁₂₁ /rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors

   Liesbeth M. Veenendaal, Hangqing Jin, Sophia Ran +6

   MaqolaOAOchiq kirish20022 iqtibos

   ABIABI:AkademIndex/2026.other.193247

5. The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA

   Mi-Ae Lyu, Lawrence H. Cheung, Walter N. Hittelman +3

   Maqola20072 iqtibos

   ABIABI:AkademIndex/2026.other.193262